METHOD FOR ASSESSING THE RISK OF DEVELOPING ALZHEIMER'S DISEASE USING A PANEL OF BLOOD PROTEINS Russian patent published in 2023 - IPC G01N33/68 G01N30/72 C07K14/47 C07K14/75 C07K14/775 C07K14/78 G01N33/58 

FIELD: medicine.

SUBSTANCE: invention relates to clinical diagnostics, and can be used to assess the risk of developing Alzheimer's disease using a panel of twenty-two proteins. The following steps are carried out: (a) sampling and sample preparation of a patient's biological sample to obtain a mixture of proteins and further chromato-mass spectrometric analysis. (b) Chromato-mass spectrometric analysis of the mixture of proteins obtained at step (a) for the purpose of quantitative analysis of proteins in a biological sample based on monitoring of multiple or selected or parallel reactions (MRM/SRM/PRM) using internal peptide standards. (c) Calculation of the probability of assigning a patient to a group of patients at risk of developing Alzheimer's disease using a trained classifier based on a panel of twenty-two proteins in a biological sample, which are afamin, thrombospondin-1, biotinidase, apolipoprotein E, serum paraoxonase/arylesterase 1, complement C1q subcomponent of B subunit, alpha-2-antiplasmin, vitronectin, apolipoprotein A-IV, fibronectin, gestation zone protein, cathelicidin antimicrobial peptide, tenascin, fibrinogen beta chain, attractin, fibrinogen gamma chain, apolipoprotein, plasminogen 1 activator inhibitor, apolipoprotein C-IV, ceruloplasmin, apolipoprotein A-II and vascular cell adhesion protein 1.

EFFECT: method provides an opportunity to assess the risk of developing Alzheimer's disease with high sensitivity and specificity for a large-scale clinical analysis of blood plasma in aged patients, both as an independent study and as a basis for creating targeted methods, due to the multiplex target (targeted) quantitative chromato-mass spectrometric analysis of a panel of 22 isotopically labeled blood plasma proteins.

8 cl, 6 dwg, 1 tbl, 3 ex